MIM
ALNY icon

Monashee Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Monashee Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,000
Closed -$600K – 44
2022
Q3 		$600K Buy
+3,000
New +$572K 0.22% 44
2019
Q3 		– Sell
-60,000
Closed -$4.35M – 117
2019
Q2 		$4.35M Buy
60,000
+56,500
+1,614% +$4.33M 1.13% 25
2019
Q1 		$327K Buy
+3,500
New +$293K 0.08% 114

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Monashee Investment Management's ALNY Position: Q4 2022 in Review

Monashee Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2022, closing a stake of 3,000 shares — an estimated $600K sold.

Monashee Investment Management first reported a position in ALNY in Q1 2019 and held it in 3 quarters. The position peaked at $4.35M in Q2 2019. 487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

  • Monashee Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Monashee Investment Management sold 3,000 Alnylam Pharmaceuticals shares in Q4 2022, an estimated $600K.
  • Monashee Investment Management first reported a position in Alnylam Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Monashee Investment Management's Alnylam Pharmaceuticals position peaked at $4.35M in Q2 2019.
  • 487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Monashee Investment Management's 13F filing for Q4 2022, filed 9 Feb 2023.